These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1969 related articles for article (PubMed ID: 9972954)

  • 1. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
    Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
    Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictably in rheumatoid arthritis patients who have begun activity after a night of bed rest.
    Manicourt DH; Poilvache P; Nzeusseu A; van Egeren A; Devogelaer JP; Lenz ME; Thonar EJ
    Arthritis Rheum; 1999 Sep; 42(9):1861-9. PubMed ID: 10513800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis.
    Steiner G; Studnicka-Benke A; Witzmann G; Höfler E; Smolen J
    J Rheumatol; 1995 Mar; 22(3):406-12. PubMed ID: 7783054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study.
    Peake NJ; Khawaja K; Myers A; Jones D; Cawston TE; Rowan AD; Foster HE
    Rheumatology (Oxford); 2005 Nov; 44(11):1383-9. PubMed ID: 16049050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis.
    Fiedorczyk M; Klimiuk PA; Sierakowski S; Gindzienska-Sieskiewicz E; Chwiecko J
    J Rheumatol; 2006 Aug; 33(8):1523-9. PubMed ID: 16881109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation between tumor necrosis factor alpha and matrix metalloproteinases levels in serum of patients with rheumatic arthritis].
    Klimiuk PA; Sierakowski S; Chwiećko J
    Pol Merkur Lekarski; 2003 May; 14(83):410-2. PubMed ID: 12939814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
    Fraser A; Fearon U; Billinghurst RC; Ionescu M; Reece R; Barwick T; Emery P; Poole AR; Veale DJ
    Arthritis Rheum; 2003 Nov; 48(11):3085-95. PubMed ID: 14613270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the concentration of plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) after total joint replacement in patients with arthritis.
    Omura K; Takahashi M; Omura T; Miyamoto S; Kushida K; Sano Y; Miura M; Nagano A
    Clin Rheumatol; 2002 Nov; 21(6):488-92. PubMed ID: 12447632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
    Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings.
    Myers A; Lakey R; Cawston TE; Kay LJ; Walker DJ
    Rheumatology (Oxford); 2004 Mar; 43(3):272-6. PubMed ID: 14523226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis.
    Martel-Pelletier J; McCollum R; Fujimoto N; Obata K; Cloutier JM; Pelletier JP
    Lab Invest; 1994 Jun; 70(6):807-15. PubMed ID: 8015285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis.
    Jain A; Nanchahal J; Troeberg L; Green P; Brennan F
    Arthritis Rheum; 2001 Aug; 44(8):1754-60. PubMed ID: 11508425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis].
    Fiedorczyk M; Klimiuk PA; Sierakowski S; Domysławska I; Chwiećko J
    Przegl Lek; 2005; 62(12):1321-4. PubMed ID: 16786739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia.
    El Messal M; Beaudeux JL; Drissi A; Giral P; Chater R; Bruckert E; Adlouni A; Chapman MJ
    Clin Chim Acta; 2006 Apr; 366(1-2):185-9. PubMed ID: 16280123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis.
    Ishiguro N; Ito T; Obata K; Fujimoto N; Iwata H
    J Rheumatol; 1996 Sep; 23(9):1599-604. PubMed ID: 8877931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin-cleaved osteopontin is increased in urine of patients with rheumatoid arthritis.
    Shio K; Kobayashi H; Asano T; Saito R; Iwadate H; Watanabe H; Sakuma H; Segawa T; Maeda M; Ohira H
    J Rheumatol; 2010 Apr; 37(4):704-10. PubMed ID: 20156944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
    Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
    J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 99.